Lilia Maria Babe, Emerald Hills, CA (US); Viktor Yuryevich Alekseyev, Palo Alto, CA (US); Neelam S Amin, Santa Monica, CA (US); Joshua Roy Basler, Palo Alto, CA (US); David A Estell, Palo Alto, CA (US); Victoria Huang, San Mateo, CA (US); David Marquez, San Jose, CA (US); Jeffrey Wayne Munos, San Francisco, CA (US); Rei Otsuka, San Mateo, CA (US); Geetha Veeramuthu, Sunnyvale, CA (US); David Edward Wildes, San Francisco, CA (US); Michelle Jackson, Newcastle Upon Tyne (GB); Euan John Magennis, Newcastle Upon Tyne (GB); Eva Maria Perez-Prat Vinuesa, Newcastle Upon Tyne (GB); Philip F. Souter, Newcastle Upon Tyne (GB); and David John Tarbit, Newcastle Upon Tyne (GB)
Assigned to Dansico US Inc., Palo Alto, CA (US)
Filed by DANISCO US INC, Palo Alto, CA (US)
Filed on Mar. 30, 2021, as Appl. No. 17/216,735.
Application 17/216,735 is a continuation of application No. 16/090,860, abandoned, previously published as PCT/US2017/030800, filed on May 3, 2017.
Claims priority of provisional application 62/331,282, filed on May 3, 2016.
Prior Publication US 2021/0292728 A1, Sep. 23, 2021
1. An isolated subtilisin variant comprising an amino acid sequence comprising a combination of amino acid substitutions X78N-X206L-X209W; wherein X is any amino acid and said variant has proteolytic activity; wherein said variant has at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1, and further wherein each amino acid position of said variant is numbered according to the corresponding amino acid position in the Bacillus amyloliquefaciens subtilisin BPN′ sequence shown in SEQ ID NO:2 as determined by alignment of the variant amino acid sequence with the BPN′ amino acid sequence.